Mitochondrial Membrane Protein-Associated Neurodegeneration — designated MPAN, OMIM #614298, also known as C19orf12-associated neurodegeneration, a rare autosomal recessive subtype of neurodegeneration with brain iron accumulation (NBIA) caused by biallelic loss-of-function mutations in the C19orf12 gene (chromosome 19 open reading frame 12) encoding a mitochondrial membrane protein of incompletely characterized function implicated in mitochondrial fatty acid synthesis, CoA metabolism, and mitochondrial bioenergetics, with disease-causing mutations including missense, nonsense, frameshift, and splice-site variants — the characteristic clinical syndrome manifests with onset typically in late childhood to early adulthood (median onset age 9–16 years) as a progressive neurodegenerative disorder combining spasticity and upper motor neuron signs (progressive gait spasticity, hyperreflexia, extensor plantar responses), extrapyramidal features with parkinsonism and dystonia, optic atrophy with progressive visual loss, peripheral neuropathy, and a prominent and often early psychiatric phenotype including depression, emotional lability, behavioral dysregulation, obsessive-compulsive features, psychosis, and cognitive decline progressing to dementia; the MRI signature is T2 hypointensity in the globus pallidus and substantia nigra reflecting pathological iron accumulation — the NBIA hallmark — often accompanied by a central T2 hyperintense streak ("eye of the tiger" pattern has been reported but is more characteristic of PKAN; in MPAN the globus pallidus iron accumulation is the consistent finding), pontine atrophy, cerebral and cerebellar atrophy as disease advances, and optic nerve atrophy; the natural history progresses over 10–30 years from first symptoms to wheelchair dependency and loss of verbal communication, with the combination of spasticity, dystonia, and progressive dementia creating a high palliative care burden in the final stages; no disease-modifying therapy has demonstrated efficacy in MPAN in clinical trials, and management is entirely symptomatic — antispastic agents (baclofen, tizanidine, intrathecal baclofen pump), dopaminergic therapy (levodopa for parkinsonian features with variable and often limited response), iron chelation therapy (deferiprone, used in PKAN and studied in NBIA broadly with limited evidence in MPAN specifically), anticonvulsants for seizures, antidepressants for the psychiatric component, and multidisciplinary supportive care.
MPAN technology platforms — encompassing the pediatric neurology and adult movement disorder specialty clinical platforms where the combination of progressive spasticity, parkinsonism, optic atrophy, and psychiatric features with characteristic MRI iron accumulation raises the MPAN diagnosis and molecular genetic confirmation is pursued, the neuroimaging platforms where brain MRI characterizes the NBIA iron deposition pattern, documents atrophy progression, and monitors treatment response, the ophthalmologic platforms where visual acuity, visual field, and optical coherence tomography (OCT) track optic atrophy progression, the neuropsychiatric platforms managing the depression, psychosis, behavioral dysregulation, and cognitive decline that are prominent MPAN features, the motor function and rehabilitation platforms documenting gait, spasticity, dystonia, and wheelchair transition timelines, the palliative care and multidisciplinary complex neurological disorder coordination platforms managing the end-stage neurological disease burden, and the C19orf12 molecular genetic testing platforms confirming the diagnosis — must maintain the availability and performance standards required by the progressive neurological complexity of MPAN management. This guide explains why MPAN tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the neurological assessment scheduling, ophthalmologic surveillance, motor function trajectory tracking, neuropsychiatric management, and palliative care coordination that define modern MPAN care.
Why MPAN Tech Platforms Require Specialized Monitoring Attention
MPAN management is defined by several clinically challenging care coordination requirements: the multi-domain progressive monitoring burden — the simultaneous progression of motor dysfunction (spasticity, parkinsonism, dystonia), visual loss (optic atrophy), neuropsychiatric disease (depression, psychosis, cognitive decline), and ultimately end-stage neurodegeneration requires longitudinal monitoring across neurology, ophthalmology, neuropsychiatry, physical/occupational/speech therapy, and palliative care platforms whose data integration determines clinical decision-making; the neuropsychiatric urgency — depression, psychosis, and behavioral dysregulation in MPAN are prominent and can be the presenting or most disabling features, requiring reliable neuropsychiatric platform availability for medication management, crisis intervention coordination, and inpatient psychiatric referral when necessary; the ophthalmologic monitoring imperative — progressive optic atrophy produces functional visual loss that drives major adaptive equipment, occupational therapy, and environmental modification decisions, requiring reliable ophthalmologic platform continuity for visual function tracking; and the palliative care complexity — the decade-long trajectory from spastic gait to wheelchair dependency to loss of communication and swallowing function requires early and sustained palliative care integration whose coordination platform availability determines comfort and quality of life in the final disease stages.
C19orf12 molecular genetic testing platforms provide the diagnostic confirmation. Biallelic C19orf12 variant identification by gene panel, exome, or genome sequencing confirms the MPAN diagnosis and enables recurrence risk counseling. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
Neurological assessment platforms document the motor progression trajectory. Spasticity rating (modified Ashworth scale), parkinsonism staging (UPDRS motor subscale), dystonia severity (Burke-Fahn-Marsden scale), cognitive assessment (MMSE, MoCA), and gait assessment require serial platform availability for the trajectory documentation that guides antispastic and dopaminergic medication adjustment. Monitor neurology platforms at 1-minute intervals during clinical hours.
Ophthalmologic platforms track progressive optic atrophy. Visual acuity, visual field testing, color vision, and OCT retinal nerve fiber layer thickness measurements track the optic atrophy trajectory that drives visual rehabilitation and adaptive equipment planning. Monitor ophthalmologic platforms at 1-minute intervals during clinical hours.
Neuropsychiatric platforms manage the psychiatric and behavioral burden. Depression, psychosis, obsessive-compulsive features, and behavioral dysregulation require regular neuropsychiatric assessment, medication management records, and crisis intervention pathway access. Monitor neuropsychiatric platforms at 1-minute intervals during clinical hours.
Palliative care and multidisciplinary coordination platforms manage end-stage disease. Advance care planning documentation, symptom management records, feeding tube decision documentation, communication augmentation planning, and caregiver support coordination require continuous platform availability across the long terminal phase of MPAN. Monitor palliative care platforms at 1-minute intervals during operational hours.
What to Monitor on an MPAN Tech Platform
Genetic Diagnosis and Molecular Confirmation
Monitor C19orf12 molecular genetic analysis records (gene panel or exome/genome sequencing — biallelic pathogenic or likely pathogenic C19orf12 variant identification; variant classification documentation; compound heterozygosity versus homozygosity; known founder variants including p.Gly58Ser common in Polish and other European populations; variant of uncertain significance escalation pathway), NBIA gene panel records (multigene NBIA panel including C19orf12, PANK2, PLA2G6, FA2H, WDR45, ATP13A2, and other NBIA genes ordered when NBIA diagnosis is clinically suspected — result segregation and confirmation), segregation analysis records (parental testing for biallelic variant confirmation, recurrence risk counseling documentation), and genetic counseling records (autosomal recessive inheritance counseling, 25% recurrence risk for siblings, carrier frequency discussion, prenatal and preimplantation testing discussion where applicable) at 1-minute intervals during laboratory hours. Alert immediately — C19orf12 molecular testing platform failures during the diagnostic evaluation of a 13-year-old presenting with progressive spastic gait, early cognitive decline, and MRI globus pallidus iron accumulation delay the NBIA subtype confirmation that determines the diagnostic label, prognosis discussion, family recurrence risk counseling, and enrollment eligibility for NBIA natural history studies.
Neurological Assessment and Motor Function Monitoring
Monitor spasticity assessment records (modified Ashworth scale at each clinic visit — upper and lower extremity spasticity grading; limb-specific and global spasticity trajectory; serial comparison to prior assessments), parkinsonism evaluation records (UPDRS motor subscale — tremor, rigidity, bradykinesia, postural instability scoring; levodopa trial response documentation — dose, duration, degree of motor improvement), dystonia severity records (Burke-Fahn-Marsden Dystonia Rating Scale — regional and total dystonia score; focal versus generalized dystonia documentation; dystonic posturing type), anticonvulsant management records (seizure episode documentation — frequency, semiology, EEG correlation; anticonvulsant choice, dose, therapeutic level monitoring, seizure response), intrathecal baclofen pump records (pump implantation date, current basal rate, bolus settings, refill schedule, pump malfunction alerts), gait and mobility assessment records (timed 10-meter walk, dynamic gait index, GMFCS level, walking aid documentation, wheelchair transition timing), and fall risk and injury records (fall frequency, fall circumstances, fall-related injury documentation, fall prevention protocol implementation) at 1-minute intervals during clinical hours. Alert immediately — spasticity assessment platform failures for a 19-year-old with MPAN whose intrathecal baclofen pump refill is scheduled prevent the pre-refill neurological assessment that confirms current basal rate appropriateness before the refill that determines the next 3–6 months of spasticity management.
Ophthalmologic Surveillance and Visual Function Tracking
Monitor visual acuity records (Snellen or ETDRS acuity — best corrected distance and near acuity at each ophthalmology visit; acuity trajectory from baseline; functional visual impairment documentation — legal blindness threshold at 20/200 or less), visual field records (Humphrey 24-2 or 30-2 automated perimetry — central scotoma, constriction pattern, severity staging; interval progression), optical coherence tomography records (OCT retinal nerve fiber layer thickness — inferior, superior, nasal, temporal quadrant RNFL measurement; ganglion cell layer thickness; optic disc cupping; interval progression rate documentation), color vision records (Ishihara or Farnsworth-Munsell color discrimination — dyschromatopsia characterization in MPAN optic atrophy), visual evoked potential records (VEP latency and amplitude — P100 wave latency prolongation and amplitude reduction correlating with optic nerve dysfunction severity), and visual rehabilitation records (low vision evaluation, magnification aids, orientation and mobility training, environmental lighting modification, assistive technology for visual impairment) at 1-minute intervals during clinical hours. Alert immediately — ophthalmologic platform failures for a 22-year-old with MPAN and rapidly progressive optic atrophy — who has lost 4 Snellen lines of acuity over the past 18 months and whose next OCT will determine whether the RNFL thickness has reached the threshold below which no further treatment-relevant monitoring is indicated — delay the visual trajectory documentation that guides the low vision rehabilitation referral and adaptive equipment decisions that must happen before functional vision is lost.
Neuropsychiatric Management
Monitor psychiatric symptom assessment records (PHQ-9 or MADRS for depression severity — monthly or quarterly in MPAN given high depression prevalence; GAD-7 for anxiety; BPRS or PANSS for psychosis — initial screening and periodic monitoring when antipsychotic medications are used; OCD symptom severity — Y-BOCS or clinical rating; behavioral dysregulation frequency documentation), psychotropic medication management records (antidepressant selection and dose — SSRI, SNRI, mirtazapine in MPAN depression; antipsychotic choice, dose, and metabolic monitoring — EPS, tardive dyskinesia monitoring critical given underlying basal ganglia pathology; mood stabilizer records), cognitive assessment records (MMSE, MoCA, RBANS at annual or semi-annual intervals — trajectory from baseline; cognitive decline rate documentation; capacity assessment when treatment decisions are made), neuropsychology evaluation records (neuropsychological battery at diagnosis and disease milestones — attention, executive function, language, visuospatial, memory; functional impact of cognitive decline), and psychiatric crisis intervention records (inpatient psychiatric admission records, emergency psychiatric evaluation records, suicidality assessment and safety planning for MPAN depression) at 1-minute intervals during clinical hours. Alert immediately — neuropsychiatric platform failures for a 17-year-old with MPAN who has developed acute psychotic symptoms in the context of known underlying psychiatric vulnerability — when the neuropsychiatry team needs platform access to review the current antipsychotic regimen, assess for drug-disease interaction with basal ganglia pathology, and determine whether inpatient psychiatric stabilization or medication adjustment can be managed in the outpatient setting — leave the treating team without the medication records needed to safely escalate or adjust psychotropic management.
Palliative Care and Multidisciplinary Coordination
Monitor palliative care assessment records (Edmonton Symptom Assessment Scale or equivalent — pain, fatigue, nausea, dyspnea, anxiety, depression, drowsiness, appetite, wellbeing at each palliative care visit; symptom trajectory), advance care planning records (goals of care discussion documentation — CPR preference, mechanical ventilation preference, artificial nutrition preference; healthcare proxy designation; POLST/MOLST form completion), swallowing assessment records (speech-language pathology dysphagia evaluation — VFSS or FEES for objective swallowing assessment; PO safety rating; thickened liquid and diet texture modification; feeding tube discussion timing), communication augmentation records (AAC device assessment and prescription — as verbal communication declines from dysarthria and cognitive involvement; partner-dependent communication system training), caregiver burden assessment records (Zarit Burden Interview or equivalent — caregiver psychological distress, respite needs, burnout assessment; social work and caregiver support documentation), and end-of-life care records (hospice eligibility discussion timing, hospice enrollment documentation, comfort-focused care transition) at 1-minute intervals during operational hours. Alert immediately — palliative care platform failures for a 28-year-old with advanced MPAN who has developed worsening dysphagia and whose family is considering gastrostomy tube placement — when the palliative care team needs to access the prior goals of care documentation to determine whether artificial nutrition is consistent with the patient's documented preferences before the surgical consultation proceeds — prevent the advance care planning integration that should precede major procedural decision-making in progressive neurological disease.
Iron Chelation and Symptomatic Therapy Management
Monitor deferiprone therapy records (deferiprone prescription in MPAN — off-label use for iron chelation; dose, adherence, CBC with differential monitoring for agranulocytosis every 2 weeks during treatment; liver function monitoring; iron studies including serum ferritin, transferrin saturation response), levodopa/carbidopa management records (levodopa trial response documentation — motor improvement, dose optimized, therapeutic plateau, response waning; dose and frequency adjustments; dyskinesia monitoring), antispastic medication records (baclofen oral — dose titration; tizanidine — dose, liver function monitoring; dantrolene — dose, liver function; intrathecal baclofen — pump logs), and neurology medication interaction records (psychiatric and neurological medication combination documentation — antidepressant selection avoiding agents with significant EPS risk in MPAN basal ganglia pathology context; anticonvulsant compatibility with levodopa and baclofen) at 1-minute intervals during clinical hours. Alert immediately — deferiprone CBC monitoring platform failures during the mandatory biweekly agranulocytosis surveillance in a 24-year-old on deferiprone interrupt the safety monitoring that is the primary constraint on iron chelation use in MPAN and other NBIA subtypes.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. MPAN management coordinates across pediatric and adult neurology, movement disorders, neuropsychiatry, ophthalmology, neuroradiology, clinical genetics, physical and occupational and speech therapy, palliative care, social work, and pharmacy — authentication failures block every team member required to execute the neurological monitoring, psychiatric management, visual surveillance, and palliative care coordination that together constitute the comprehensive MPAN care model.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, neurology monitoring portals, ophthalmology platforms, neuropsychiatric management systems, palliative care documentation platforms, and rehabilitation coordination portals. Certificate errors disrupt the multi-specialist data sharing and record access on which integrated MPAN management depends.
HIPAA and Rare Neurogenetic Disorder Patient Privacy Considerations
MPAN technology platforms handle highly sensitive PHI for a patient population small enough (estimated low hundreds of diagnosed individuals globally) that re-identification risk is substantial. Records include C19orf12 molecular genetic analysis (heritable autosomal recessive mutation with 25% sibling recurrence risk), progressive neurological disease trajectory documentation, detailed psychiatric and cognitive assessment records (depression, psychosis, dementia), visual disability progression records, advance care planning documents with explicit CPR and artificial nutrition preferences, and end-of-life care documentation. The combination of genetic testing records with psychiatric records creates a dual privacy sensitivity requiring GINA compliance for the genetic component and heightened HIPAA protections for the psychiatric component under applicable state mental health privacy laws in addition to the base HIPAA Privacy and Security Rule.
Alerting Strategy for MPAN Tech Platforms
Immediate 24/7 alerting for authentication: MPAN care spans neurology, neuropsychiatry, ophthalmology, palliative care, and pharmacy; authentication failures at any hour block urgent care.
Immediate laboratory-hours alerting for genetic testing platforms: C19orf12 molecular confirmation is the diagnostic gate that triggers prognostic counseling, family testing, and registry enrollment.
Immediate clinical-hours alerting for neurological assessment platforms: Motor function tracking, intrathecal baclofen pump management, and levodopa response documentation drive real-time medication decisions.
Immediate clinical-hours alerting for ophthalmologic platforms: Optic atrophy is progressive and irreversible; visual function trajectory data drives major adaptive equipment and rehabilitation decisions.
Immediate clinical-hours alerting for neuropsychiatric platforms: Depression, psychosis, and behavioral crisis in MPAN require real-time platform access for medication management and crisis intervention pathway activation.
Immediate operational-hours alerting for palliative care platforms: Advance care planning documentation and goals of care records are time-critical when major procedural or comfort-care decisions are being made.
Sustained-failure alert (10–15 minutes): Rehabilitation coordination, caregiver support, and rare disease registry platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms MPAN platform availability from the geographies where NBIA specialty centers, C19orf12 molecular testing programs, neuropsychiatric services for rare neurological diseases, low vision rehabilitation programs, and palliative care neurology programs concentrate.
Status Page for MPAN Care Team Communication
A real-time status page gives neurologists managing progressive spasticity and parkinsonism, neuropsychiatrists managing the psychiatric phenotype, ophthalmologists tracking optic atrophy, movement disorder specialists trialing iron chelation, palliative care teams coordinating end-stage management, and genetics teams counseling families about recurrence risk immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in MPAN care coordination documents, intrathecal baclofen pump emergency protocols, and advance care planning update procedures.
Vigilmon Setup for MPAN Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | C19orf12 molecular genetic testing | 1 min | Slack + PagerDuty (lab hours) | | NBIA gene panel and segregation analysis | 1 min | Slack + PagerDuty (lab hours) | | Spasticity assessment (modified Ashworth scale) | 1 min | Slack + PagerDuty (clinical hours) | | Parkinsonism evaluation (UPDRS motor) | 1 min | Slack + PagerDuty (clinical hours) | | Dystonia severity (Burke-Fahn-Marsden) | 1 min | Slack + PagerDuty (clinical hours) | | Intrathecal baclofen pump records | 1 min | Slack + PagerDuty (clinical hours) | | Levodopa/carbidopa response monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Deferiprone CBC monitoring (agranulocytosis) | 1 min | Slack + PagerDuty (lab hours) | | Visual acuity and visual field | 1 min | Slack + PagerDuty (clinical hours) | | OCT retinal nerve fiber layer | 1 min | Slack + PagerDuty (clinical hours) | | VEP and color vision | 2 min | Slack + PagerDuty (clinical hours) | | Psychiatric symptom assessment (PHQ-9, PANSS) | 1 min | Slack + PagerDuty (clinical hours) | | Psychotropic medication management | 1 min | Slack + PagerDuty (clinical hours) | | Cognitive assessment (MMSE, MoCA) | 1 min | Slack + PagerDuty (clinical hours) | | Psychiatric crisis pathway | 1 min | Slack + PagerDuty (24/7) | | Palliative care symptom assessment | 1 min | Slack + PagerDuty (operational hours) | | Advance care planning documentation | 1 min | Slack + PagerDuty (operational hours) | | Swallowing assessment and feeding tube documentation | 1 min | Slack + PagerDuty (clinical hours) | | AAC device and communication augmentation | 2 min | Slack (business hours) | | Caregiver burden assessment and social work | 2 min | Slack (business hours) | | NBIA registry and research coordination | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure C19orf12 molecular genetic testing platforms with immediate laboratory-hours alerting
- Add NBIA gene panel platforms with immediate laboratory-hours alerting
- Configure spasticity, parkinsonism, and dystonia assessment platforms with immediate clinical-hours alerting
- Add intrathecal baclofen pump management platforms with immediate clinical-hours alerting
- Configure levodopa response monitoring platforms with immediate clinical-hours alerting
- Add deferiprone CBC monitoring platforms with immediate laboratory-hours alerting — biweekly agranulocytosis surveillance is non-negotiable
- Configure visual acuity and visual field platforms with immediate clinical-hours alerting
- Add OCT retinal nerve fiber layer platforms with immediate clinical-hours alerting
- Configure psychiatric symptom assessment platforms with immediate clinical-hours alerting
- Add psychotropic medication management platforms with immediate clinical-hours alerting
- Configure psychiatric crisis pathway platforms with 24/7 immediate alerting
- Add palliative care symptom assessment platforms with immediate operational-hours alerting
- Configure advance care planning documentation platforms with immediate operational-hours alerting
- Add swallowing assessment and feeding tube documentation platforms with immediate clinical-hours alerting
- Configure AAC and communication augmentation platforms with sustained-failure alerting
- Add caregiver support and social work platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all genetic, neurology, ophthalmology, psychiatric, palliative care, and rehabilitation platforms
- Add the status page URL to MPAN care coordination documents, baclofen pump protocols, and psychiatric crisis pathway materials
Conclusion
MPAN technology platforms are embedded in clinical decisions where neuropsychiatric platform availability for a 21-year-old with MPAN who has been hospitalized twice in the past year for acute psychotic episodes — when the outpatient neuropsychiatry team needs platform access at an early morning urgent appointment to review the current antipsychotic and antidepressant regimen, assess for medication-disease interaction with the patient's progressive basal ganglia pathology, and determine whether dose escalation, switch to an atypical antipsychotic with lower EPS burden, or inpatient psychiatric referral is indicated before the patient's behavioral dysregulation precipitates a third hospitalization — cannot be disrupted by platform failures that leave the treating team without the medication records, prior hospitalization summaries, and neurological monitoring data needed to safely titrate psychiatric medications in a patient with both neurological and psychiatric disease; where ophthalmologic platform availability for a 25-year-old with MPAN and documented progressive optic atrophy — when the annual low vision evaluation must proceed and the current best-corrected acuity and OCT data must be reviewed against the prior year's measurements to determine whether the acuity has declined to the threshold that triggers an orientation and mobility training referral, a white cane assessment, and an augmentative communication evaluation before the concurrent cognitive and visual losses combine to make these adaptive interventions more difficult to implement — cannot be disrupted by scheduling platform failures that delay the visual trajectory documentation that determines when adaptive interventions must begin; and where palliative care documentation platform availability for a 32-year-old with advanced MPAN who can no longer communicate verbally and whose family is meeting with the care team to discuss gastrostomy tube placement — when the advance care planning documentation completed at age 26 when the patient still had decision-making capacity must be accessible to determine whether artificial nutrition was part of the patient's documented goals before the surgical consultation proceeds — cannot be disrupted by platform failures that prevent access to the advance directive that gives the patient's prior expressed preferences their rightful authority over the medical decision being made in the patient's absence. A neuropsychiatric platform unavailable when acute psychosis in MPAN requires urgent medication review, an ophthalmologic platform interrupted when visual trajectory documentation determines adaptive intervention timing, a palliative care documentation platform unavailable when advance care planning must guide a major medical decision — these are not IT incidents. They are clinical disruptions in the management of a rare progressive neurodegenerative disorder whose multi-domain complexity, prominent psychiatric vulnerability, progressive visual loss, and end-stage palliative care burden make platform operational continuity the infrastructure on which multi-specialist, dignity-preserving, preference-honoring MPAN care depends.
Uptime monitoring gives MPAN tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to NBIA specialty centers, neuropsychiatric services, ophthalmologic programs, palliative care teams, and compliance auditors that platform operational reliability matches the progressive neurological monitoring intensity, psychiatric management urgency, visual rehabilitation precision, and palliative care documentation standards of modern MPAN care.
Start monitoring your MPAN care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #MPAN #C19orf12 #NBIA #neurodegeneration #brain #iron #accumulation #spasticity #parkinsonism #optic #atrophy #dystonia #deferiprone #intrathecal #baclofen #neuropsychiatric #palliative #care #rare #genetic #disorder #HIPAA #healthtech #digitalhealth #uptime #sre